This report was updated on June 18, 2025 to remove two funds on page 5 that did not close in 2025 and were not oversubscribed. It was also updated on July 21 to correct the deal values of two funds in a table on page 21.
Biotech VC performance patterns emerge from complete market cycle
An in-depth analysis of biotech VC from 2012 to 2024 reveals a complete investment cycle, with market activity rising, peaking, and returning to historical levels. The findings highlight performance shifts between biotech and non-biotech strategies, along with structural and regional changes in capital allocation.
Key findings from the 2025 PitchBook report on biotech VC:
Complete market cycle: The biotech VC ecosystem progressed through a full boom-bust-reset cycle, shaped by changing capital costs, exit market conditions, and sector-level reallocations. The return to baseline levels may indicate a more sustainable foundation for the next phase of life sciences investing.
Performance differentiation: Biotech VC funds significantly outperformed non-biotech VC counterparts in recent vintages, reversing earlier periods when non-biotech strategies delivered higher returns. The data underscores the advantage of sector expertise during periods of capital constraint and market volatility.
Regional and structural changes: North America continues to lead in biotech VC activity, while other regions—particularly Asia—have seen relative declines. Capital has become increasingly concentrated in larger vehicles and institutional platforms, reflecting the continued evolution of the VC market structure.
Why it matters for investors and fund managers
This analysis provides investors and fund managers with a data-driven view of biotech VC performance and structural trends. As the market recalibrates, long-term returns are increasingly linked to specialized expertise, selective deployment, and alignment with emerging innovation priorities.
Table of contents
| Key takeaways | 1 |
| Introduction: Biotech VC fund ecosystem | 2 |
| Biotech VC capital flows from 2012 to 2024: A boom and a recalibration | 2 |
| Regional biotech investment: Innovation hubs and emerging markets | 8 |
| Biotech capital concentration: The fund-size spectrum and investment strategies | 11 |
| Biotech investment returns: The specialization premium and performance analysis | 13 |
| Outlook: Navigating the next frontier of life science capital | 17 |
| Appendix: Select lists of biotech investors | 19 |